NordiQC EQA Data and Observations for PD-L1 Biomarker Testing By Søren Nielsen, Director, NordiQC Immune-checkpoint inhibitors targeting PD-1 or PD-L1 as pembrolizumab, nivolumab, durvalumab and atezolizumab have since 2016 been approved for multiple cancers as lung carcinoma, urothelial carcinoma, melanoma, breast carcinoma and many other solid cancers. At present Immunohistochemistry (IHC) for PD-L1 expression is read more…